Literature DB >> 27988238

Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses.

Simon P Kim1, Steven C Campbell2, Inderbir Gill3, Brian R Lane4, Hein Van Poppel5, Marc C Smaldone6, Alessandro Volpe7, Alexander Kutikov8.   

Abstract

BACKGROUND: While partial nephrectomy (PN) is the recommended treatment for many small renal masses, anatomically complex tumors necessitate a clear understanding of the potential risks and benefits of PN and radical nephrectomy (RN).
OBJECTIVE: To critically review the comparative effectiveness evidence of PN versus RN; to describe key trade-offs involved in this treatment decision; and to highlight gaps in the current literature. EVIDENCE ACQUISITION: A collaborative critical review of the medical literature was conducted. EVIDENCE SYNTHESIS: Patients who undergo PN for an anatomically complex or large mass may be exposed to perioperative and potential oncologic risks that could be avoided if RN were performed, while patients who undergo RN may forgo long-term benefits of renal preservation. Decision-making regarding the optimal treatment with PN or RN among patients with anatomically complex or large renal mass is highly nuanced and must balance the risks and benefits of each approach. Currently, high-quality evidence on comparative effectiveness is sparse. Retrospective comparisons are plagued by selection biases, while the one existing prospective randomized trial, albeit imperfect, suggests that nephron-sparing surgery may not benefit all patients.
CONCLUSIONS: For anatomically complex tumors, PN preserves renal parenchyma but may expose patients to higher perioperative risks than RN. The risks and benefits of each surgical approach must be better objectified for identification of patients most suitable for complex PN. A prospective randomized trial is warranted and would help in directing patient counseling. PATIENT
SUMMARY: Treatment decisions for complex renal masses require shared decision-making regarding the risk trade-offs between partial and radical nephrectomy.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Partial nephrectomy; Radical nephrectomy; Renal cell carcinoma; Renal masses; Surgery

Mesh:

Year:  2016        PMID: 27988238     DOI: 10.1016/j.eururo.2016.11.038

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  13 in total

1.  Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis.

Authors:  Lei Shi; Yan He; Chang Liu; Xiaoyuan Qian; Zhixian Wang
Journal:  Cancer Med       Date:  2020-09-05       Impact factor: 4.452

2.  Renal function after kidney surgery: "it's tough to make predictions, especially about the future".

Authors:  John M DiBianco; Patrick T Gomella; Mark W Ball
Journal:  Ann Transl Med       Date:  2019-07

3.  Prediction of significant estimated glomerular filtration rate decline after renal unit removal to aid in the clinical choice between radical and partial nephrectomy in patients with a renal mass and normal renal function.

Authors:  Andrew G McIntosh; Daniel C Parker; Brian L Egleston; Robert G Uzzo; Mohammed Haseebuddin; Shreyas S Joshi; Rosalia Viterbo; Richard E Greenberg; David Y T Chen; Marc C Smaldone; Alexander Kutikov
Journal:  BJU Int       Date:  2019-06-30       Impact factor: 5.588

4.  Partial nephrectomy in solitary kidneys: comparison between open surgery and robotic-assisted laparoscopy on perioperative and functional outcomes (UroCCR-54 study).

Authors:  Ygal Benichou; François Audenet; Karim Bensalah; Morgan Roupret; Philippe Paparel; Cedric Lebacle; Franck Bruyère; Jean-Baptiste Beauval; Arnauld Villers; Hervé Lang; Xavier Durand; Pierre Bigot; Jean Alexandre Long; Cécile Champy; Alexandre Lavolle; Jean Christophe Bernhard; Eric Alezra
Journal:  World J Urol       Date:  2022-06-20       Impact factor: 4.226

5.  Ischemia Techniques in Nephron-sparing Surgery: A Systematic Review and Meta-Analysis of Surgical, Oncological, and Functional Outcomes.

Authors:  Francesco Greco; Riccardo Autorino; Vincenzo Altieri; Steven Campbell; Vincenzo Ficarra; Inderbir Gill; Alexander Kutikov; Alex Mottrie; Vincenzo Mirone; Hendrik van Poppel
Journal:  Eur Urol       Date:  2018-10-13       Impact factor: 24.267

6.  Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer.

Authors:  Jan Ebbing; Felix Menzel; Paolo Frumento; Kurt Miller; Bernhard Ralla; Tom Florian Fuller; Jonas Busch; Justin William Collins; Christofer Adding; Hans Helge Seifert; Peter Ardelt; Christian Wetterauer; Timm Westhoff; Carsten Kempkensteffen
Journal:  BMC Nephrol       Date:  2019-02-04       Impact factor: 2.388

Review 7.  Role of minimally invasive partial nephrectomy in the management of renal mass.

Authors:  Randall A Lee; David Strauss; Alexander Kutikov
Journal:  Transl Androl Urol       Date:  2020-12

8.  Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma.

Authors:  Janine Bacic; Tao Liu; R Houston Thompson; Stephen A Boorjian; Bradley C Leibovich; Dragan Golijanin; Boris Gershman
Journal:  Urology       Date:  2020-03-04       Impact factor: 2.649

9.  Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.

Authors:  Yuqing Wu; Saisai Chen; Minhao Zhang; Kuangzheng Liu; Jibo Jing; Kehao Pan; Lihua Zhang; Bin Xu; Xiaoming Lu; Ming Chen
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

10.  Robot-assisted versus laparoscopic partial nephrectomy for anatomically complex T1b renal tumors with a RENAL nephrometry score ≥7: A propensity score-based analysis.

Authors:  Wen Deng; Junhua Li; Xiaoqiang Liu; Luyao Chen; Weipeng Liu; Xiaochen Zhou; Jingyu Zhu; Bin Fu; Gongxian Wang
Journal:  Cancer Med       Date:  2019-12-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.